These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 36671484)
21. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
22. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD. Chen H; Chen Q Int J Biol Sci; 2022; 18(12):4756-4767. PubMed ID: 35874945 [TBL] [Abstract][Full Text] [Related]
23. Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. Zhao SW; Li YM; Li YL; Su C World J Gastroenterol; 2023 Jan; 29(2):241-256. PubMed ID: 36687127 [TBL] [Abstract][Full Text] [Related]
24. Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination. Nevola R; Criscuolo L; Beccia D; Delle Femine A; Ruocco R; Imbriani S; Alfano M; Villani A; Russo A; Perillo P; Marfella R; Adinolfi LE; Sasso FC; Marrone A; Rinaldi L World J Gastroenterol; 2023 Feb; 29(5):800-814. PubMed ID: 36816617 [TBL] [Abstract][Full Text] [Related]
26. COVID-19 and comorbidities of hepatic diseases in a global perspective. Ahmad A; Ishtiaq SM; Khan JA; Aslam R; Ali S; Arshad MI World J Gastroenterol; 2021 Apr; 27(13):1296-1310. PubMed ID: 33833483 [TBL] [Abstract][Full Text] [Related]
27. COVID-19-related liver injury: Mechanisms, diagnosis, management; its impact on pre-existing conditions, cancer and liver transplant: A comprehensive review. Vinutha M; Sharma UR; Swamy G; Rohini S; Vada S; Janandri S; Haribabu T; Taj N; Gayathri SV; Jyotsna SK; Mudagal MP Life Sci; 2024 Nov; 356():123022. PubMed ID: 39214285 [TBL] [Abstract][Full Text] [Related]
28. Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma. Pazgan-Simon M; Kucharska M; Górka-Dynysiewicz J; Simon K Pharmacol Rep; 2022 Dec; 74(6):1306-1314. PubMed ID: 36394820 [TBL] [Abstract][Full Text] [Related]
29. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. Hartl L; Haslinger K; Angerer M; Jachs M; Simbrunner B; Bauer DJM; Semmler G; Scheiner B; Eigenbauer E; Strassl R; Breuer M; Kimberger O; Laxar D; Trauner M; Mandorfer M; Reiberger T Liver Int; 2022 Jun; 42(6):1297-1307. PubMed ID: 35412018 [TBL] [Abstract][Full Text] [Related]
30. Molecular and cellular mechanisms of liver dysfunction in COVID-19. Huang C; Li Q; Xu W; Chen L Discov Med; 2020; 30(160):107-112. PubMed ID: 33382966 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups. Liatsos GD World J Gastroenterol; 2023 Apr; 29(16):2397-2432. PubMed ID: 37179584 [TBL] [Abstract][Full Text] [Related]
32. COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. Ekpanyapong S; Bunchorntavakul C; Reddy KR J Viral Hepat; 2022 Jan; 29(1):4-20. PubMed ID: 34352133 [TBL] [Abstract][Full Text] [Related]
33. The Impact of COVID-19 on Liver Injury. Dawood DRM; Salum GM; El-Meguid MA Am J Med Sci; 2022 Feb; 363(2):94-103. PubMed ID: 34752738 [TBL] [Abstract][Full Text] [Related]
34. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. McGrowder DA; Miller F; Anderson Cross M; Anderson-Jackson L; Bryan S; Dilworth L Diseases; 2021 Jul; 9(3):. PubMed ID: 34287285 [TBL] [Abstract][Full Text] [Related]
35. COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells. Ali FEM; Abd El-Aziz MK; Ali MM; Ghogar OM; Bakr AG World J Gastroenterol; 2023 Jan; 29(3):425-449. PubMed ID: 36688024 [TBL] [Abstract][Full Text] [Related]
36. Management of COVID-19 patients with chronic liver diseases and liver transplants. Hu X; Sun L; Guo Z; Wu C; Yu X; Li J Ann Hepatol; 2022; 27(1):100653. PubMed ID: 34929350 [TBL] [Abstract][Full Text] [Related]
37. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Ferron PJ; Gicquel T; Mégarbane B; Clément B; Fromenty B Biochimie; 2020 Dec; 179():266-274. PubMed ID: 32891697 [TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease. Choaib A; Issa E; El Choueiry F; Eldin JN; Shbaklo K; Alhajj M; Sawaya RT; Assi G; Nader M; Chatila R; Faour WH Inflamm Res; 2023 Feb; 72(2):301-312. PubMed ID: 36539655 [TBL] [Abstract][Full Text] [Related]
39. COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms. Du M; Yang S; Liu M; Liu J Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101793. PubMed ID: 34428501 [TBL] [Abstract][Full Text] [Related]
40. Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19. Tripon S; Bilbault P; Fabacher T; Lefebvre N; Lescuyer S; Andres E; Schmitt E; Garnier-KepKA S; Borgne PL; Muller J; Merdji H; Chaffraix F; Mutter D; Baumert TF; Meziani F; Doffoel M Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101894. PubMed ID: 35227956 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]